Composite polypeptide solid beverage with uric acid reducing function and preparation method of composite polypeptide solid beverage

Abstract

The invention relates to the technical field of functional beverages, in particular to a composite polypeptide solid beverage with a uric acid reducing function and a preparation method of the composite polypeptide solid beverage. The composite polypeptide solid beverage with the uric acid reducing function is prepared from the following raw materials in percentage by weight: 15-25% of plukenetia volubilis extract, 30-40% of lysimachia christinae hance-plantain herb composite extract, 8-12% of oyster peptide powder, 5-8% of earthworm protein peptide freeze-dried powder and 3-5% of a flavoring agent. Wherein the ratio of a lysimachia christinae hance extract to a plantain herb extract in the lysimachia christinae hance-plantain herb composite extract is 3: The flavoring agent is erythritol and / or stevioside, xanthine oxidase is inhibited by using flavonoid substances, GLUT9 expression is synergistically down-regulated by using bispyribaloside, PRPP synthetase activity is regulated by using zinc-rich peptide, uric acid micro-crystals are dissolved by using earthworm protein peptide, a multi-target action network of flavonoid-glycoside-bioactive peptide is achieved, and the effect of improving the bioavailability of the flavonoid-glycoside-bioactive peptide is achieved. And triple mechanisms of excretion promotion, generation inhibition and kidney protection are realized.

Description

Technical Field

[0001] This invention relates to the field of functional beverage technology, specifically to a compound polypeptide solid beverage with uric acid-lowering function and its preparation method. Background Technology

[0002] With the improvement of people's living standards and changes in lifestyle, the incidence of hyperuricemia (HUA) is increasing year by year. HUA is caused by increased uric acid production and / or decreased renal uric acid secretion. Its most common clinical manifestation is gout, which seriously affects patients' physical and mental health and quality of life. Although HUA is not a fatal disease, it can induce a variety of serious diseases such as myocardial infarction, coronary heart disease, diabetes, hyperlipidemia, metabolic syndrome, and chronic kidney disease. Therefore, HUA has become a metabolic disease that seriously affects people's daily lives and threatens their health.

[0003] The prevention and treatment of hyperuricemia primarily relies on medication, mostly used after hyperuricemia has progressed to gout. Treatment options include chemical drugs and traditional Chinese medicine. Chemical drugs primarily treat acute gout attacks with colchicine and non-salicylic acid NSAIDs, while chronic gout medications mainly fall into four categories: drugs that reduce uric acid synthesis targeting key enzymes in purine metabolism; drugs that excrete uricosuric agents targeting renal tubular uricosuric transporters; dual inhibitors of xanthine oxidoreductase and renal tubular uricosuric transporters; and uricase, which promotes uric acid conversion and excretion. Traditional Chinese medicine treatments for gout include the compound formula Simiao San, and single-herb formulas such as ginkgo biloba, rhubarb, polygonum cuspidatum, and red peony root. However, these medications all have certain limitations; poor efficacy and significant side effects are bottlenecks in their clinical application, especially in long-term use to lower uric acid or prevent uric acid elevation, where unavoidable difficulties exist.

[0004] Given the limited availability of uric acid-lowering drugs and their shortcomings in safety, efficacy, and cost-effectiveness, it is essential to research and develop health / functional foods that are derived from medicinal and dietary sources and are safe and effective in lowering uric acid. This research has significant social and economic value. Summary of the Invention

[0005] The purpose of this invention is to at least solve one of the technical problems existing in the prior art, and to provide a compound polypeptide solid beverage with uric acid-lowering function and its preparation method.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows: a compound polypeptide solid beverage with uric acid lowering function, composed of the following raw materials in weight percentage: 15-25% of star oil vine extract, 30-40% of moneywort-plantain compound extract, 8-12% of oyster peptide powder, 5-8% of earthworm protein peptide freeze-dried powder, and 3-5% of flavoring agent.

[0007] Furthermore, the ratio of Lysimachia christinae extract to Plantago asiatica extract in the Lysimachia christinae-Plantago asiatica compound extract is 3:2.

[0008] Furthermore, the flavoring agents are erythritol and / or steviosides.

[0009] Furthermore, the extract of *Stellaria media* is obtained by the following method: *Stellaria media* to be extracted is weighed, ground, and placed into an extraction vessel, where it is thoroughly mixed with a portion of 50% ethanol. Then, CO2 from a gas storage tank is heated by a booster pump and brought to a supercritical state. This CO2 is then pumped into a premixer and thoroughly mixed with the remaining 50% ethanol. The valve is then opened, and the mixture enters the extraction vessel for supercritical CO2 extraction. After the effective components of *Stellaria media* are extracted, they enter a separator along with the supercritical CO2. The temperature and pressure are then increased and decreased. The supercritical CO2 returns to normal and separates from the effective components. High-purity, impurity-free *Stellaria media* extract is collected from the bottom of the extraction vessel.

[0010] Furthermore, the supercritical CO2 flow rate is 3-5 L / h, the extraction temperature is 40-45℃, and the extraction pressure is 10-25 MPa.

[0011] Furthermore, the Lysimachia christinae extract and Plantago asiatica extract are obtained by the following method: high-quality Lysimachia christinae and Plantago asiatica are selected, and after impurity removal and drying, they are pulverized and passed through a 20-40 mesh sieve; the Lysimachia christinae powder and Plantago asiatica powder obtained after sieving are respectively subjected to thermal extraction with ethanol, filtered, and the extracts are respectively spray-dried to obtain the Lysimachia christinae extract and Plantago asiatica extract.

[0012] Furthermore, the volume fraction of ethanol is 50-60%; the thermal extraction is performed at 50℃~70℃ for 5~8 hours, repeated three times, and the extracts from the three extractions are combined.

[0013] Furthermore, the oyster peptide powder is obtained by the following method: high-quality oysters are enzymatically hydrolyzed with a compound flavor protease and trypsin at 45±2℃, and the resulting hydrolysate is spray-dried at 160℃ to obtain the oyster peptide powder.

[0014] Furthermore, the earthworm protein peptide lyophilized powder is obtained by the following method: earthworm is enzymatically hydrolyzed with a compound flavor protease and trypsin at 37±1℃, the resulting hydrolysate is mixed with a sodium alginate-chitosan composite drug delivery system, and then freeze-dried to obtain earthworm protein peptide lyophilized powder.

[0015] A method for preparing a compound polypeptide solid beverage with uric acid-lowering function includes the following steps: mixing each component evenly according to the stated mass percentage, sterilizing, obtaining the compound polypeptide solid beverage with uric acid-lowering function, and dispensing the obtained solid beverage into bags in an aseptic packaging workshop.

[0016] Compared with the prior art, the technical solution of this application has the following beneficial effects:

[0017] 1. This application utilizes extracts of *Stellaria media*, *Lysimachia christinae* and *Plantago asiatica*, oyster peptide powder, and freeze-dried earthworm protein peptide powder to achieve the following: flavonoids inhibit xanthine oxidase; spicoside synergistically downregulates GLUT9 expression, which enhances URAT1 transport and promotes excretion; zinc-rich peptides regulate PRPP synthase activity; and earthworm protein peptides dissolve uric acid microcrystals. Furthermore, this dual-peptide complex can repair renal tubular epithelial cells to form targeted protection, achieving a multi-target action network of flavonoids, glycosides, and bioactive peptides. This not only inhibits uric acid synthesis in the body but also promotes diuresis and excretion of uric acid.

[0018] 2. This invention is a composition formed by combining extracts of star oil vine, compound extracts of moneywort and plantain, oyster peptide powder, freeze-dried powder of earthworm protein peptide and flavoring agent. Its ingredients are natural, healthy, and have no toxic side effects. It is suitable for long-term use and can be developed into a health care or functional food for long-term use by people with high uric acid to achieve the effect of lowering uric acid and realize the triple mechanism of promoting excretion, inhibiting production and protecting the kidney. Detailed Implementation

[0019] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments.

[0020] Example 1

[0021] A compound polypeptide solid beverage with uric acid-lowering function is composed of the following raw materials by weight percentage: 15% *Stellaria media* extract, 30% *Lysimachia christinae*-*Plantago asiatica* compound extract, 8% oyster peptide powder, 5% *Earthworm protein peptide* freeze-dried powder, and 3% flavoring agent. The ratio of *Lysimachia christinae* extract to *Plantago asiatica* extract in the *Lysimachia christinae*-*Plantago asiatica* compound extract is 3:2, thereby achieving synergistic enhancement of URAT1 transport and promoting excretion. The flavoring agent is erythritol and / or steviol glycosides, which utilize flavonoids to inhibit xanthine oxidase, utilize the synergistic downregulation of GLUT9 expression using flavonoid glycosides, utilize zinc-rich peptides to regulate PRPP synthase activity, and utilize earthworm protein peptides to dissolve uric acid microcrystals, achieving a multi-target action network of flavonoids-glycosides-bioactive peptides. This not only inhibits the synthesis of uric acid in the body but also promotes diuresis and excretion of uric acid.

[0022] As a preferred embodiment of the present invention, it may also have the following additional technical features: The extract of *Stellaria media* is obtained by the following method: *Stellaria media* to be extracted is weighed, ground, and then placed in an extraction vessel and thoroughly mixed with a portion of 50% ethanol. CO2 in a gas storage tank is then heated by a heater using a booster pump to enter a supercritical state. This supercritical CO2 is pumped into a premixer and thoroughly mixed with the remaining 50% ethanol. The valve is then opened, and the mixture enters the extraction vessel for supercritical CO2 extraction. After the effective components in *Stellaria media* are extracted, they enter a separator along with the supercritical CO2, where the temperature and pressure are increased and decreased. The supercritical CO2 returns to normal and separates from the effective components. High-purity, impurity-free *Stellaria media* extract is collected from the bottom of the extraction vessel. The flow rate of the supercritical CO2 is 3-5 L / h, the extraction temperature is 40-45℃, and the extraction pressure is 10-25 MPa. This allows the obtained flavonoids to inhibit xanthine oxidase.

[0023] In this embodiment, the extracts of Lysimachia christinae and Plantago asiatica were obtained by the following method: high-quality Lysimachia christinae and Plantago asiatica were selected, purified, dried, pulverized, and passed through a 20-40 mesh sieve. The Lysimachia christinae powder and Plantago asiatica powder obtained after sieving were respectively subjected to thermal extraction with ethanol, filtered, and the extracts were spray-dried to obtain the Lysimachia christinae extract and Plantago asiatica extract, wherein the volume fraction of ethanol was 50-60%. The thermal extraction was carried out at 50℃-70℃ for 5-8 hours, repeated three times, and the extracts from the three extractions were combined. This achieves synergistic downregulation of GLUT9 expression by two herbicides, enhancing URAT1 transport and promoting excretion.

[0024] In this embodiment, the oyster peptide powder is obtained by the following method: high-quality oysters are enzymatically hydrolyzed with a compound flavor protease and trypsin at 45±2℃, and the resulting hydrolysate is spray-dried at 160℃ to obtain the oyster peptide powder. The molecular weight of the oyster peptide powder is <1000Da, and the zinc-rich peptide regulates the activity of PRPP synthase.

[0025] In this embodiment, the earthworm protein peptide lyophilized powder is obtained by the following method: earthworm is enzymatically hydrolyzed with compound flavor protease and trypsin at 37±1℃, the resulting hydrolysate is mixed with sodium alginate-chitosan composite drug delivery system, and then freeze-dried to obtain earthworm protein peptide lyophilized powder. The fibrinolytic activity of the earthworm protein peptide lyophilized powder is ≥2000IU / g, which can dissolve uric acid microcrystals.

[0026] A method for preparing a compound polypeptide solid beverage with uric acid-lowering function includes the following steps: mixing each component evenly according to the stated mass percentage, sterilizing, obtaining the compound polypeptide solid beverage with uric acid-lowering function, and dispensing the obtained solid beverage into bags in an aseptic packaging workshop.

[0027] Example 2

[0028] A compound polypeptide solid beverage with uric acid-lowering function is composed of the following raw materials by weight percentage: 20% *Stellaria media* extract, 35% *Lysimachia christinae*-*Plantago asiatica* compound extract, 10% oyster peptide powder, 6% *Earthworm protein peptide* freeze-dried powder, and 4% flavoring agent. The ratio of *Lysimachia christinae* extract to *Plantago asiatica* extract in the *Lysimachia christinae*-*Plantago asiatica* compound extract is 3:2. The preparation method is described in Example 1.

[0029] Example 3

[0030] A compound polypeptide solid beverage with uric acid-lowering function is composed of the following raw materials by weight percentage: 25% *Stellaria media* extract, 40% *Lysimachia christinae*-*Plantago asiatica* compound extract, 12% oyster peptide powder, 8% *Earthworm protein peptide* freeze-dried powder, and 5% flavoring agent. The ratio of *Lysimachia christinae* extract to *Plantago asiatica* extract in the *Lysimachia christinae*-*Plantago asiatica* compound extract is 3:2. The preparation method is described in Example 1.

[0031] Performance testing

[0032] The compound polypeptide solid beverage with uric acid-lowering function described in Examples 1-3, the allopurinol group, and the single-ingredient group (the single-ingredient group contained only one of the following: *Stellaria media* extract, *Lysimachia christinae*-*Plantago asiatica* compound extract, oyster peptide powder, and *Earthworm* protein peptide freeze-dried powder) were fed to rats with hyperuricemia (n=30). Data were observed after 7 days, as shown in the table below:

[0033]

[0034]

[0035] The above tests show that: flavonoids from *Stellaria media* extract can inhibit xanthine oxidase; succinate glycosides can synergistically downregulate GLUT9 expression, which can enhance URAT1 transport and promote excretion; zinc-rich peptides can regulate PRPP synthase activity; and earthworm protein peptides can dissolve uric acid microcrystals. Furthermore, this dual-peptide complex can repair renal tubular epithelial cells and form targeted protection, achieving a multi-target action network of flavonoids, glycosides, and bioactive peptides. This not only inhibits the synthesis of uric acid in the body but also promotes diuresis and excretion of uric acid.

[0036] Provided there is no conflict, those skilled in the art can freely combine and use the above-mentioned additional technical features.

[0037] It is understood that the present invention has been described through some embodiments, and those skilled in the art will recognize that various changes or equivalent substitutions can be made to these features and embodiments without departing from the spirit and scope of the invention. Furthermore, under the teachings of the present invention, these features and embodiments can be modified to adapt to specific situations and materials without departing from the spirit and scope of the invention. Therefore, the present invention is not limited to the specific embodiments disclosed herein, and all embodiments falling within the scope of the claims of this application are within the protection scope of the present invention.

Claims

1. A compound polypeptide solid beverage with uric acid-lowering function, characterized in that, It is composed of the following raw materials by weight percentage: 15-25% *Stellaria media* extract, 30-40% *Lysimachia christinae*-*Plantago asiatica* compound extract, 8-12% oyster peptide powder, 5-8% *Earthworm protein peptide freeze-dried powder, and 3-5% flavoring agent.

2. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The ratio of Lysimachia christinae extract to Plantago asiatica extract in the Lysimachia christinae-Plantago asiatica compound extract is 3:

2.

3. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The flavoring agent is erythritol and / or steviol glycosides.

4. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The Star Oil Vine extract is obtained by the following method: Star Oil Vine to be extracted is weighed, ground, and then placed into an extraction vessel and thoroughly mixed with a portion of 50% ethanol. CO2 from the gas storage tank is then heated through a heater using a booster pump to enter a supercritical state. This supercritical CO2 is then pumped into a premixer and thoroughly mixed with the remaining 50% ethanol. The valve is then opened to allow the CO2 to enter the extraction vessel for supercritical CO2 extraction. After the effective components of the Star Oil Vine are extracted, they enter a separator along with the supercritical CO2. The temperature and pressure are then increased and decreased. The supercritical CO2 returns to normal and separates from the effective components. High-purity, impurity-free Star Oil Vine extract is collected from the bottom of the extraction vessel.

5. The compound polypeptide solid beverage with uric acid-lowering function according to claim 4, characterized in that: The supercritical CO2 flow rate is 3-5 L / h, the extraction temperature is 40-45℃, and the extraction pressure is 10-25 MPa.

6. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The Lysimachia christinae extract and Plantago asiatica extract are obtained by the following method: high-quality Lysimachia christinae and Plantago asiatica are selected, and after impurity removal and drying, they are pulverized and passed through a 20-40 mesh sieve; the Lysimachia christinae powder and Plantago asiatica powder obtained after sieving are respectively thermally extracted with ethanol, filtered, and the extracts are spray-dried to obtain the Lysimachia christinae extract and Plantago asiatica extract.

7. The compound polypeptide solid beverage with uric acid-lowering function according to claim 6, characterized in that: The volume fraction of ethanol is 50-60%; the thermal extraction is carried out at 50℃~70℃ for 5~8 hours, repeated three times, and the extracts from the three extractions are combined.

8. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The oyster peptide powder is obtained by the following method: high-quality oysters are enzymatically hydrolyzed with compound flavor protease and trypsin at 45±2℃, and the resulting hydrolysate is spray-dried at 160℃ to obtain the oyster peptide powder.

9. The compound polypeptide solid beverage with uric acid-lowering function according to claim 1, characterized in that: The earthworm protein peptide freeze-dried powder is obtained by the following method: earthworm is enzymatically hydrolyzed with compound flavor protease and trypsin at 37±1℃, the resulting hydrolysate is mixed with sodium alginate-chitosan composite drug delivery system, and then freeze-dried to obtain earthworm protein peptide freeze-dried powder.

10. A method for preparing a compound polypeptide solid beverage with uric acid-lowering function, characterized in that: The preparation of the compound polypeptide solid beverage with uric acid lowering function according to any one of claims 1-9 includes the following steps: mixing each component evenly according to the said mass percentage, sterilizing, obtaining the compound polypeptide solid beverage with uric acid lowering function, and dispensing the obtained solid beverage into bags in an inner packaging aseptic workshop.

Images